SCHEMBL868374

SCHEMBL868374

F[C]1CCCCCC1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197665 0.97
SCHEMBL562816 0.88
SCHEMBL9850 0.72
SCHEMBL2386257 0.70 KMT2A (0.52)
SCHEMBL27940361 0.70
SCHEMBL28137041 0.70
SCHEMBL25392652 0.67
SCHEMBL611774 0.67
SCHEMBL22032676 0.67
SCHEMBL27657579 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118344370-A Isoindolinone and indazole compounds for EGFR degradation C4医药公司 2024-07-16 CN disclosed
CN-118286210-A Application of Artemisia princeps 中国科学院上海有机化学研究所 2024-07-05 CN disclosed
CN-114901277-B Isoindolinone and indazole compounds for EGFR degradation C4医药公司 2024-05-17 CN disclosed
US-20240158418-A1 EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS C4 THERAPEUTICS, INC. (US) 2024-05-16 US disclosed
CN-117940123-A Application of hydrazide compound in treatment of tumor 南京施江医药科技有限公司 2024-04-26 CN disclosed
EP-4357338-A1 N-SUBSTITUTED PHENYLSULFONAMIDE COMPOUND AND USE THEREOF Shanghai Leado Pharmatech Co. Ltd. (CN) 2024-04-24 EP disclosed
US-20240124445-A1 BENZENE RING COMPOUND AND USE THEREOF NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD (CN) 2024-04-18 US disclosed
EP-4347044-A2 EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS C4 Therapeutics, Inc. (US) 2024-04-10 EP disclosed
US-20240076300-A1 ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR C4 THERAPEUTICS, INC. (US) 2024-03-07 US disclosed
CN-117529474-A N-substituted phenyl sulfonamide compound and application thereof 上海璃道医药科技有限公司 2024-02-06 CN disclosed
US-20140080816-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES AbbVie Deutschland GmbH & Co. KG (DE) 2014-03-20 US disclosed
US-20140080813-A1 TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES ABBVIE DEUTSCHLAND (DE) 2014-03-20 US disclosed
WO-2013083568-A1 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, AND USE THEREOF TO PRODUCE DRUGS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-13 WO disclosed
US-8455648-B2 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3) ABBOTT GMBH & CO. KG (DE) 2013-06-04 US disclosed
EP-2297154-B1 1- (7-(HEXAHYDROPYRROLO [3, 4-C]PYRROL-2 (1H) -YL) QUIN0LIN-4-YL) -3- (PYRAZIN-2-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK-3) INHIBITORS ABBOTT GMBH & CO KG (DE) 2013-04-03 EP disclosed
US-8318793-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors ABBOTT GMBH & CO. KG (DE) 2012-11-27 US disclosed
US-20120172376-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS ABBOTT GMBH & CO. KG (DE) 2012-07-05 US disclosed
US-20120077840-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS ABBOTT GMBH & CO. KG (DE) 2012-03-29 US disclosed
US-20110105528-A1 1-(7-(HEXAHYDROPYRROLO [3, 4-C] PYRROL-2 (1H)-YL) QUINOLIN-4-YL) -3- (PYRAZIN-2-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK-3) ABBOTT GMBH & CO. KG (DE) 2011-05-05 US disclosed
US-20110003810-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS ABBOTT GMBH & CO. KG (DE) 2011-01-06 US disclosed